MBX Stock Analysis: Buy, Sell, or Hold?
MBX - MBX Biosciences, Inc. Common Stock
$26.92
-1.58 (-5.54%)
▼
5d:
-4.34%
30d:
-17.3%
90d:
-12.88%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 11, 2026
Get Alerted When MBX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MBX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: MBX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: MBX is currently trading at $26.92, which is considered oversold relative to its 30-day fair value range of $27.65 to $33.88.
Technical Outlook: Technically, MBX is in a uptrend. The price is currently testing key support at $26.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $61.30 (+115.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MBX is in a uptrend. The price is currently testing key support at $26.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $61.30 (+115.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$27.65 -
$33.88
Company Quality Score
53/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.5%)
- BULLISH: Trading 115.1% below Wall St target ($61.30)
Fair Price Analysis
30-Day Fair Range
$27.65 -
$33.88
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.47
(12.9%)
Support & Resistance Levels
Support Level
$26.80
Resistance Level
$29.88
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.72
Wall Street Target
$61.30
(+115.1%)
Share & Embed Analysis
Last updated: March 30, 2026 4:48 PM ET
Data refreshes hourly during market hours. Next update: 5:48 PM
Data refreshes hourly during market hours. Next update: 5:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MBX showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
P. Kent Hawryluk
BUY
18500 shares
2026-03-13
P. Kent Hawryluk
BUY
20000 shares
2025-10-20
Steven L Hoerter
BUY
20000 shares
2025-10-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 67 BUY |
